Boobs are just the beginning. If there is one company that can grow new organs, limbs, and bone...and you can buy shares of it right now, before anyone else knows it exists, how does that sound?
That’s how a national magazine led off an article about the miracle of regenerative medicine.
But it's not just boobs...
Modern biotech companies are literally changing life as we know it, and they’re making life-changing profits in the process.
This miracle means patients with breasts lost to surgery — as well as women who are simply unhappy with their own bodies — can now re-grow new ones with raw materials harvested from their own body fat.
Think about that for a moment.
Then think about the fortunes that will be made as this technology is used to grow new organs, regenerate limbs, and eradicate disease as we know it…
You may have already heard of some of these buzzwords:
- tissue engineering
- cell therapy
- regenerative medicine
Today, they’re as real as your morning sunrise.
Regenerative medicine is a relatively new field that brings together experts in biology, chemistry, computer science, engineering, genetics, medicine and robotics, among others, to find solutions to some of the most challenging problems faced by the medical community.
Its essence is much simpler: to harness the body’s natural healing processes and activate these processes when and where they're critically needed.
"The reason this technology works is that it's not really surgery," explains Dr. Anthony Atala, one of the field's most renowned researchers. According to Atala, doctors using these techniques are essentially "just priming the pump" by putting the appropriate cells into the appropriate place, and asking the body to do the rest.
I've reported before on the reasons these methods have allowed Dr. Atala and his team to make history of their own. Between 2004 and 2007, Atala successfully reconstructed urethras in five young patients using the patients' own cells.
With their made-to-order implants now in place for more than five years, Atala reports, "These children are now totally normal... They're running around and doing the things they usually do."
The Investor's Edge
While the success of regenerative medicine cannot be denied, this portion of the biotech sector is still practically brand-new.
But that "investor's edge" isn't likely to last long, according to Life Science Intelligence. The firm projects the global market for tissue-regenerative products could be worth more than $118 billion in just three years. By comparison, today's market stands at roughly $1.8 million.
Now try, if you can, to imagine how much money is going to be made in this arena over the next three years and beyond as these successes take hold in the market...
It could be life-changing in its own right.
I've discovered a company whose scientists are creating living, functional tissue to repair or replace organ function lost to age, disease, or congenital defects. To call what they do “revolutionary” doesn't do it justice...
It is nothing less than science fiction brought to life.
Your bargain-hunting analyst,
Steve Christ
Wealth Daily, Copyright © 2011, Angel Publishing LLC, P.O. Box 84905, Phoenix, AZ 85071. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Wealth Daily does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.
Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription
